留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

移植肿瘤学开创肝移植治疗肝癌新时代

韩承祚 卫强 徐骁

韩承祚, 卫强, 徐骁. 移植肿瘤学开创肝移植治疗肝癌新时代[J]. 临床肝胆病杂志, 2021, 37(2): 253-256. DOI: 10.3969/j.issn.1001-5256.2021.02.002
引用本文: 韩承祚, 卫强, 徐骁. 移植肿瘤学开创肝移植治疗肝癌新时代[J]. 临床肝胆病杂志, 2021, 37(2): 253-256. DOI: 10.3969/j.issn.1001-5256.2021.02.002
HAN CZ, WEI Q, XU X. Transplant oncology creates a new era of liver transplantation for the treatment of liver cancer[J]. J Clin Hepatol, 2021, 37(2): 253-256. DOI: 10.3969/j.issn.1001-5256.2021.02.002
Citation: HAN CZ, WEI Q, XU X. Transplant oncology creates a new era of liver transplantation for the treatment of liver cancer[J]. J Clin Hepatol, 2021, 37(2): 253-256. DOI: 10.3969/j.issn.1001-5256.2021.02.002

移植肿瘤学开创肝移植治疗肝癌新时代

DOI: 10.3969/j.issn.1001-5256.2021.02.002
基金项目: 

国家自然科学基金 81930016

国家自然科学基金 81625003

浙江省重点研发计划 2019C03050

浙江省重点研发计划 2021C03118

详细信息
    作者简介:

    韩承祚(1996—),女,主要从事肝胆胰外科和器官移植研究

    通讯作者:

    徐骁,zjxu@zju.edu.cn

  • 作者贡献声明:韩承祚负责文献检索和撰写论文;卫强负责撰写及修改论文;徐骁负责拟定写作思路、指导撰写文章并最后定稿。
  • 中图分类号: R735.7;R617

Transplant oncology creates a new era of liver transplantation for the treatment of liver cancer

  • 摘要: 近年来,外科学、肿瘤学、免疫学、药学和影像学等深度交叉融合,逐渐形成了新兴学科——移植肿瘤学。 随着移植肿瘤学的发展,肝移植在肝胆胰恶性肿瘤的治疗中发挥了越来越关键的作用。 回溯移植肿瘤学的发展并总结其特点,重点阐述移植肿瘤学发展在肝癌精准诊治,尤其是肝癌肝移植受者选择、供肝来源拓展中发挥的重要作用,强调肝癌肝移植术后肿瘤复发防治及其机制的探索仍是移植肿瘤学研究的重点攻关方向。
  • [1] ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1
    [2] LAI Q, AVOLIO AW, GRAZIADEI I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation[J]. Liver Transpl, 2013, 19(10): 1108-1118. DOI: 10.1002/lt.23706
    [3] MEHTA N, YAO FY. Hepatocellular cancer as indication for liver transplantation: Pushing beyond Milan[J]. Curr Opin Organ Transplant, 2016, 21(2): 91-98. DOI: 10.1097/MOT.0000000000000282
    [4] MORAY G, KARAKAYALI F, YILMAZ U, et al. Expanded criteria for hepatocellular carcinoma and liver transplantation[J]. Transplant Proc, 2007, 39(4): 1171-1174. DOI: 10.1016/j.transproceed.2007.02.056
    [5] DUBAY D, SANDROUSSI C, SANDHU L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion[J]. Ann Surg, 2011, 253(1): 166-172. DOI: 10.1097/SLA.0b013e31820508f1
    [6] ITO T, TAKADA Y, UEDA M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation[J]. Liver Transpl, 2007, 13(12): 1637-1644. DOI: 10.1002/lt.21281
    [7] KIM JM, KWON CH, JOH JW, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma[J]. Transplant Proc, 2014, 46(3): 726-729. DOI: 10.1016/j.transproceed.2013.11.037
    [8] JONAS S, MITTLER J, PASCHER A, et al. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center[J]. Liver Transpl, 2007, 13(6): 896-903. DOI: 10.1002/lt.21189
    [9] YAO FY, FERRELL L, BASS NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403. DOI: 10.1053/jhep.2001.24563
    [10] XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513
    [11] YANG MD, CHEN WY, LU D, et al. Advances in the application of liquid biopsy in organ transplantation[J/CD]. Chin J Transplant (Electronic Edition), 2020, 14(2): 124-127.

    杨墨丹, 陈文彦, 鲁迪, 等. 液体活检在器官移植领域的应用进展[J/CD]. 中华移植杂志(电子版), 2020, 14(2): 124-127.
    [12] XU X, CHEN J, WEI Q, et al. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition)[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(4): 307-312. DOI: 10.1016/j.hbpd.2019.06.010
    [13] HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: A new MORAL to the story[J]. Ann Surg, 2017, 265(3): 557-564. DOI: 10.1097/SLA.0000000000001966
    [14] MAGGIORE U, PASCUAL J. The bad and the good news on cancer immunotherapy: Implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5): 312-316. DOI: 10.1053/j.ackd.2016.08.002
    [15] NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617
    [16] WANG J, CHEN JW, ZHENG GR, et al. Evolution and development of surgical treatment for liver cancer[J]. J Clin Hepatol, 2020, 36(10): 2161-2166. DOI: 10.3969/j.issn.1001-5256.2020.10.001

    王捷, 陈茄威, 郑国荣, 等. 肝癌外科治疗的演变与发展[J]. 临床肝胆病杂志, 2020, 36(10): 2161-2166. DOI: 10.3969/j.issn.1001-5256.2020.10.001
    [17] Committee of Liver Transplantation, Chinese College of Transplant Doctors, Chinese Medical Doctor Association; Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese expert consensus on application of sirolimus in liver transplantation for hepatocellular carcinoma (2020 edition)[J]. J Clin Hepatol, 2020, 36(11): 2429-2434. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.11.007

    中国医师协会器官移植医师分会肝移植学组, 中华医学会器官移植学分会肝移植学组. 西罗莫司在肝癌肝移植中应用的中国专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(11): 2429-2434. DOI: 10.3969/j.issn.1001-5256.2020.11.007
    [18] MEHTA N, DODGE JL, ROBERTS JP, et al. Alpha-fetoprotein decrease from > 1, 000 to < 500 ng/ml in patients with hepatocellular carcinoma leads to improved posttransplant outcomes[J]. Hepatology, 2019, 69(3): 1193-1205.
    [19] HUANG S, JIANG F, WANG Y, et al. Diagnostic performance of tumor markers AFP and PIVKA-Ⅱ in Chinese hepatocellular carcinoma patients[J]. Tumour Biol, 2017, 39(6): 1010428317705763.
    [20] WEI Q, YANG MF, ZHOU ZS, et al. Therapeutic efficacy analysis of ABO incompatible liver transplantation for hepatocellular carcinoma[J]. Chin J Organ Transplant, 2020, 41(5): 275-280. (in Chinese) DOI: 10.3760/cma.j.cn421203-20200411-00114

    卫强, 杨梦凡, 周之晟, 等. ABO血型不相容肝移植治疗肝癌的疗效分析[J]. 中华器官移植杂志, 2020, 41(5): 275-280. DOI: 10.3760/cma.j.cn421203-20200411-00114
    [21] MANFREDI S, LEPAGE C, HATEM C, et al. Epidemiology and management of liver metastases from colorectal cancer[J]. Ann Surg, 2006, 244(2): 254-259. DOI: 10.1097/01.sla.0000217629.94941.cf
    [22] ABREU P, GORGEN A, OLDANI G, et al. Recent advances in liver transplantation for cancer: The future of transplant oncology[J]. JHEP Rep, 2019, 1(5): 377-391. DOI: 10.1016/j.jhepr.2019.07.004
    [23] HAGNESS M, FOSS A, LINE PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer[J]. Ann Surg, 2013, 257(5): 800-806. DOI: 10.1097/SLA.0b013e3182823957
    [24] YAO JC, HASSAN M, PHAN A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-3072. DOI: 10.1200/JCO.2007.15.4377
    [25] SOGA J, YAKUWA Y, OSAKA M. Carcinoid syndrome: A statistical evaluation of 748 reported cases[J]. J Exp Clin Cancer Res, 1999, 18(2): 133-141.
    [26] MAZZAFERRO V, PULVIRENTI A, COPPA J. Neuroendocrine tumors meta static to the liver: How to select patients for liver transplantation?[J]. J Hepatol, 2007, 47(4): 460-466. DOI: 10.1016/j.jhep.2007.07.004
    [27] MEYERS RL, TIAO GM, DUNN SP, et al. Surgical management of children with locally advanced hepatoblastoma[J]. Cancer, 2012, 118(16): 4090-4091; author reply 4094-4095. DOI: 10.1002/cncr.26715
    [28] ZSÍROS J, MAIBACH R, SHAFFORD E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study[J]. J Clin Oncol, 2010, 28(15): 2584-2590. DOI: 10.1200/JCO.2009.22.4857
    [29] ORTEGA JA, DOUGLASS EC, FEUSNER JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group[J]. J Clin Oncol, 2000, 18(14): 2665-2675. DOI: 10.1200/JCO.2000.18.14.2665
    [30] Compilation and Examination Expert Group for Guidelines for the diagnosis and treatment of hepatoblastoma (2019). Guidelines for the diagnosis and treatment of hepatoblastoma (2019)[J]. J Clin Hepatol, 2019, 35(11): 2431-2434. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.11.008

    儿童肝母细胞瘤诊疗规范(2019年版)编写审定专家组. 儿童肝母细胞瘤诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2019, 35(11): 2431-2434. DOI: 10.3969/j.issn.1001-5256.2019.11.008
  • 加载中
计量
  • 文章访问数:  57
  • HTML全文浏览量:  12
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-23
  • 修回日期:  2020-12-23
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回